HLA
ALIM

Hamilton Lane Advisors’s Alimera Sciences ALIM Stock Holding History

Hamilton Lane Advisors’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,886
Closed -$240K – 63
2014
Q4 		$240K Buy
2,886
+1,553
+117% +$126K 0.09% 47
2014
Q3 		$108K Buy
+1,333
New +$114K 0.04% 54

Other funds holding ALIM

SM
Scale Management Foster City, California $359M AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Hamilton Lane Advisors's ALIM Position: Q1 2015 in Review

Hamilton Lane Advisors sold out of Alimera Sciences (ALIM) in Q1 2015, closing a stake of 2,886 shares — an estimated $240K sold.

Hamilton Lane Advisors first reported a position in ALIM in Q3 2014 and held it in 2 quarters. The position peaked at $240K in Q4 2014. 64 funds tracked by Wall St. Rank hold ALIM as of Q1 2015.

  • Hamilton Lane Advisors reported no remaining Alimera Sciences position as of Q1 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 2,886 Alimera Sciences shares in Q1 2015, an estimated $240K.
  • Hamilton Lane Advisors first reported a position in Alimera Sciences in Q3 2014 and held it in 2 quarters.
  • Hamilton Lane Advisors's Alimera Sciences position peaked at $240K in Q4 2014.
  • 64 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2015.

Based on Hamilton Lane Advisors's 13F filing for Q1 2015, filed 8 Apr 2015.